Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.
about
Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in micePharmacology of nociceptin and its receptor: a novel therapeutic targetPeptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agentsDiscovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptorsCharacterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptorsPharmacological properties of nociceptin/orphanin FQ-induced stimulation and inhibition of cyclic AMP formation in distinct layers of rat olfactory bulbInhibitory action of nociceptin/orphanin FQ on functionally different thalamic neurons in urethane-anaesthetized ratsNew peptide inhibitors of type IB topoisomerases: similarities and differences vis-a-vis inhibitors of tyrosine recombinases.In vitro and direct in vivo testing of mixture-based combinatorial libraries for the identification of highly active and specific opiate ligands.Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1,3,8-triaza-spiro[4. 5]dec-3-yl)-acetic acid methyl ester (NNC 63-0532) is a novel potent nociceptin receptor agonist.BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mousFurther characterization of the ORL1 receptor-mediated inhibition of noradrenaline release in the mouse brain in vitroStructural requirements of N-substituted spiropiperidine analogues as agonists of nociceptin/orphanin FQ receptorPharmacological Profile of Nociceptin/Orphanin FQ Receptors Interacting with G-Proteins and β-Arrestins 2.Rare diseases and orphan drugs.In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptorActivities of mixed NOP and mu-opioid receptor ligands.Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic PainActivity of new NOP receptor ligands in a rat peripheral mononeuropathy model: potentiation of morphine anti-allodynic activity by NOP receptor antagonists.A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applicationsNociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.Pharmacological Profiles of Oligomerized μ-Opioid Receptors.Antagonism by acetyl-RYYRIK-NH2 of G protein activation in rat brain preparations and of chronotropic effect on rat cardiomyocytes evoked by nociceptin/orphanin FQ.Characterization of the ORL(1) receptor on adrenergic nerves in the rat anococcygeus muscle.The design and synthesis of a novel quinolizidine template for potent opioid and opioid receptor-like (ORL1, NOP) receptor ligands.ZP120 causes relaxation by pre-junctional inhibition of noradrenergic neurotransmission in rat mesenteric resistance arteries.In Vitro and In Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential.Characterization of [Nphe(1)]nociceptin(1-13)NH(2), a new selective nociceptin receptor antagonist.Probing ligand recognition of the opioid pan antagonist AT-076 at nociceptin, kappa, mu, and delta opioid receptors through structure-activity relationships.Partial agonist behaviour depends upon the level of nociceptin/orphanin FQ receptor expression: studies using the ecdysone-inducible mammalian expression system.Inhibition of striatal and retinal dopamine release via nociceptin/orphanin FQ receptors.Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.Functional pharmacological characterization of SER100 in cardiovascular health and disease.Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile
P2860
Q24672947-E0E59AD8-A02F-4B3C-A73B-473F08071B31Q24675084-DA2D1150-276F-4994-BA35-B69DAB052F6EQ28178485-AD097A1F-A5A3-4E65-93B0-87817D3B3889Q28256196-38A5C756-F2E5-4E52-923A-7B402B656647Q28344581-2FE88909-131F-436F-AB56-FE71A28643BAQ28344895-9962EF21-1654-49CF-880B-176DD5496FD4Q28358694-CA71985C-8299-46AE-A0EF-1151E828946CQ30826416-0EBF3FA2-1BB1-497A-9118-97FA15AD3148Q33247770-5CD3B5C5-A6E6-458B-B489-E0E22A6B60E8Q33662208-01B99960-541A-4568-9800-73DC23D30151Q33923177-0E63468A-D122-4EDD-8424-DEA516139210Q34423181-D6269B97-12A8-4472-A951-5376D9BEF75EQ34702273-16EC053B-E73F-4B03-9C35-9D28A501F542Q35028805-5739167B-7D5C-49F9-B104-5968166EC6A1Q35669512-E4863397-DF11-4475-9A7F-1041B7552E59Q35738904-2F1D988E-6EBC-4E2C-BEFE-A8B4A37B6872Q35827448-A8DDF08E-19EC-4DC0-BCA4-B92EA089E003Q35989343-C8BFE021-ADB3-40FF-9146-EB1F97C05974Q36456876-8994765D-ECB8-4004-B4A4-D8D39D4B787DQ36744366-EA333B15-35EB-43B1-923C-67D0C9D5F8F2Q36849604-3F654B6D-D746-4162-8677-E5BB080AEB14Q37343674-D03BDA16-84E2-48D8-B5A9-B2DA0EEC9DD2Q37367805-89F751D1-BD30-4BD8-B26D-37EBE121B9CCQ37444456-1A90A5E4-4911-4983-A8AF-8966D4E1203DQ37444462-CCA4B46C-30C1-4CDE-947E-3856153D57D5Q37679197-73D977EA-5F04-4065-8C16-7406F0BA20C8Q41788694-DF908FAD-0FC0-4C0A-8E23-39F54B02DA3DQ41885308-5FEB1204-0990-40D5-9D06-977A6729FF81Q41889844-715CF0A9-E901-47A7-8B67-207EF22F5E92Q42012961-69ADBF84-A511-45CE-BBA0-75530BC752D2Q42067858-5144FDDE-F771-4D83-9509-2DB7FD1C6DC7Q42150123-DE3BDACE-0566-44EE-8287-C4B6F309E721Q42378885-047A3E14-C2B2-4BC5-BD87-A062B85BD7FBQ42447404-D6BF59AA-9F31-45F4-9508-0EA3286921F3Q42699951-B9CF19DB-A4C0-4F2C-BCDB-9B24631AB5E3Q43165858-67145C34-90D4-496B-AF01-37CECBE25898Q47130638-D3F093C2-3B3F-428C-A47D-9E43FF38EE20Q57073139-E106688D-A2C0-4443-9C64-C5955C303D4C
P2860
Binding and in vitro activities of peptides with high affinity for the nociceptin/orphanin FQ receptor, ORL1.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Binding and in vitro activitie ...... in/orphanin FQ receptor, ORL1.
@en
type
label
Binding and in vitro activitie ...... in/orphanin FQ receptor, ORL1.
@en
prefLabel
Binding and in vitro activitie ...... in/orphanin FQ receptor, ORL1.
@en
P2093
P1476
Binding and in vitro activitie ...... tin/orphanin FQ receptor, ORL1
@en
P2093
Berzetei-Gurske IP
Houghten RA
P304
P407
P577
1997-11-01T00:00:00Z